Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (9693)	7/8/1998 9:52:00 PM
From: Ron Luhmann	Respond to of 14328

great news on the product line acquisition... the Celts are excellent deal makers...I'm not nearly as pleased on the bone thrown to the "B" warrant holders...having burned 10,000 "A's" not long ago...you pay your money... you take your chances...mgmt reversing their decision to extend makes me wonder what else they will reverse themselves on...issuance of more shares?...not sour grapes...just the principle of a decision that was already made... still very long TRIBY ... market wasn't as impressed with the product line acquisition as the warrant extension... underway in OKINAWA ... Ron

To: Keiko who wrote (9693)	7/9/1998 11:00:00 AM
From: John Lacelle	Read Replies (1) \| Respond to of 14328

Keiko, That is interesting about CMTR about to fall. SDS is going down too, and I have heard some ugly news about QDEL as well. It could be that TRIBY will be one of the survivors after the shake- out that is coming with small-caps in the med diagnostic field. The main problem I see with this company is that testing platforms may continue to favor the "high-tech" end of the market. What I mean is that the better, more reliable ways to test will continue to be ELIZA or RIA based upon some kind of computerized operating system. I was at one time enthralled with the idea of simple one-shot kits for HIV, HV, and other viral infections designed much in the way of those 1 minute pregnancy tests you see in markets. However, it seems that for the time being, most tests will continue to be conducted in a med lab. Sorry to continue to be a bear but I think Abbott, Smithkline, and the other heavys will continue to dominate this market. -john

To: Keiko who wrote (9693)	7/12/1998 4:02:00 AM
From: milton	Respond to of 14328

Keiko Look at how the other bios are trumpeting their value. See biz.yahoo.com Bioi is another bio that I own and follow. Following on your Eire trip, if you have any of the ears of triby management, is there any chance they may be interested in attending the bio conferences which give companies exposure. It has been a complaint that triby has made little effort in this area. I applaud triby's past focus on building a solid company. But some effort to realize value by educating investors has a plus side-- greater capitalization in the market and better access to financing. That way triby doesn't have to resort to warrants and other such gimmicks.